

Title (en)
TRANSDERMAL THERAPEUTIC SYSTEMS WITH CRYSTALLIZATION-INHIBITING PROTECTIVE FILM (RELEASE LINER)

Title (de)
TRANSDERMALE THERAPEUTISCHE SYSTEME MIT KRISTALLISATIONINHIBIERENDER SCHUTZFOLIE (RELEASE LINER)

Title (fr)
SYSTÈMES THÉRAPEUTIQUES TRANSDERMIQUES À FEUILLE DE PROTECTION INHIBANT LA CRISTALLISATION (RELEASE LINER)

Publication
EP 2613771 A1 20130717 (DE)

Application
EP 11757808 A 20110902

Priority

- DE 102010040299 A 20100906
- EP 2011065204 W 20110902

Abstract (en)
[origin: CA2810103A1] The invention relates to pharmaceutical formulations, in particular to transdermal therapeutic systems, which are characterized in that no active substance crystallizes out at the interface between the removable release liner and the active-substance-containing matrix. The active substance is gestodene or a gestodene ester in supersaturated matrix polymer and/or ethynyl estradiol. The matrix is free from solubilizers, crystallization inhibitors and dispersants.

IPC 8 full level
A61K 9/70 (2006.01)

CPC (source: EA EP IL KR US)
A61K 9/70 (2013.01 - EA IL KR US); **A61K 9/703** (2013.01 - EA EP IL US); **A61K 9/7053** (2013.01 - EA EP IL US); **A61P 5/30** (2017.12 - EP IL); **A61P 15/18** (2017.12 - EP IL); **A61P 17/00** (2017.12 - EP IL)

Citation (search report)
See references of WO 2012031985A1

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)
BA ME

DOCDB simple family (publication)
DE 102010040299 A1 20120308; AP 2013006787 A0 20130430; AP 3586 A 20160210; AR 082907 A1 20130116; AU 2011298892 A1 20130328; AU 2011298892 B2 20150312; BR 112013005305 A2 20160816; CA 2810103 A1 20120315; CA 2810103 C 20190618; CL 2013000636 A1 20130913; CN 103079549 A 20130501; CN 103079549 B 20161102; CO 6690753 A2 20130617; CR 20130098 A 20130515; CU 20130031 A7 20130531; CU 24172 B1 20160425; DO P2013000053 A 20130715; EA 032575 B1 20190628; EA 201390246 A1 20130930; EC SP13012477 A 20130430; EP 2613771 A1 20130717; GT 201300062 A 20150116; IL 224980 A 20170731; IL 251124 A0 20170430; IL 251124 B 20200730; JP 2013536828 A 20130926; JP 2016216500 A 20161222; JP 6104800 B2 20170329; KR 20130114127 A 20131016; MA 34581 B1 20131002; MX 2013002602 A 20130408; MY 162768 A 20170714; NZ 607630 A 20150227; PE 20131138 A1 20131026; PE 20180198 A1 20180126; SG 10201506927T A 20151029; SG 187941 A1 20130430; TN 2013000087 A1 20140625; TW 201217165 A 20120501; TW I576245 B 20170401; UA 110217 C2 20151210; US 2012082714 A1 20120405; US 2014018751 A1 20140116; US 8557279 B2 20131015; US 9060955 B2 20150623; UY 33590 A 20111031; WO 2012031985 A1 20120315; ZA 201301389 B 20210526

DOCDB simple family (application)
DE 102010040299 A 20100906; AP 2013006787 A 20110902; AR P110103250 A 20110906; AU 2011298892 A 20110902; BR 112013005305 A 20110902; CA 2810103 A 20110902; CL 2013000636 A 20130306; CN 201180042701 A 20110902; CO 13045117 A 20130306; CR 20130098 A 20130306; CU 20130031 A 20110902; DO 2013000053 A 20130306; EA 201390246 A 20110902; EC SP13012477 A 20130306; EP 11757808 A 20110902; EP 2011065204 W 20110902; GT 201300062 A 20130306; IL 22498013 A 20130228; IL 25112417 A 20170313; JP 2013526490 A 20110902; JP 2016161929 A 20160822; KR 20137008726 A 20110902; MA 35706 A 20130304; MX 2013002602 A 20110902; MY PI2013700339 A 20110902; NZ 60763011 A 20110902; PE 2013000383 A 20110902; PE 2017001638 A 20110902; SG 10201506927T A 20110902; SG 2013013453 A 20110902; TN 2013000087 A 20130305; TW 100132149 A 20110906; UA A201304320 A 20110902; US 201113225660 A 20110906; US 201314028990 A 20130917; UY 33590 A 20110905; ZA 201301389 A 20130222